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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation
of human platelets
Milenko Cicmil, Joanne M. Thomas, Mireille Leduc, Cassian Bon, and Jonathan M. Gibbins
Platelet endothelial cell adhesion mole-
cule-1 (PECAM-1/CD31) is a 130-kd trans-
membrane glycoprotein and a member of
the growing family of receptors with im-
munoreceptor tyrosine-based inhibitory
motifs (ITIMs). PECAM-1 is expressed on
platelets, certain T cells, monocytes, neu-
trophils, and vascular endothelial cells
and is involved in a range of cellular
processes, though the role of PECAM-1
in platelets is unclear. Cross-linking of
PECAM-1 results in phosphorylation of
the ITIM allowing the recruitment of signal-
ing proteins that bind by way of Src-
homology domain 2 interactions. Pro-
teins that have been implicated in the
negative regulation of cellular activation
by ITIM-bearing receptors include the ty-
rosine phosphatases SHP-1 and SHP-2.
Tyrosine phosphorylation of immunore-
ceptor tyrosine-based activatory motif
(ITAM)–bearing receptors such as the col-
lagen receptor GPVI-Fc receptor -chain
complex on platelets leads to activation.
Increasing evidence suggests that ITIM-
and ITAM-containing receptors may act
antagonistically when expressed on the
same cell. In this study it is demonstrated
that cross-linking PECAM-1 inhibits the
aggregation and secretion of platelets in
response to collagen and the GPVI-selec-
tive agonist convulxin. In these experi-
ments thrombin-mediated platelet aggre-
gation and secretion were also reduced,
albeit to a lesser degree than for collagen,
suggesting that PECAM-1 function may
not be restricted to the inhibition of ITAM-
containing receptor pathways. PECAM-1
activation also inhibited platelet protein
tyrosine phosphorylation stimulated by
convulxin and thrombin; this was accom-
panied by inhibition of the mobilization of
calcium from intracellular stores. These
data suggest that PECAM-1 may play a
role in the regulation of platelet function
in vivo. (Blood. 2002;99:137-144)
© 2002 by The American Society of Hematology
Introduction
Platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) is
a 130-kd membrane-spanning glycoprotein whose expression is
restricted to several hematopoietic cell types including platelets,
monocytes, neutrophils, certain T lymphocytes, and vascular
endothelial cells.1-4 The functions of PECAM-1 are diverse and
include angiogenesis,5 vasculogenesis,6 integrin regulation,7,8 trans-
endothelial migration of leukocytes,9-11 and T- and B-cell antigen
receptor function,12,13 though the role of this molecule in platelets is
unclear. When PECAM-1 was cloned, it was assigned to the family
of cell adhesion molecules on the basis of structural similarities.4
PECAM-1 is involved in adhesion, though much attention has been
directed recently to studying its ability to participate in signal
transduction. The cytoplasmic tail of PECAM-1 contains a con-
served motif called an immunoreceptor tyrosine-based inhibitory
motif (ITIM), which underlies its signaling properties and is shared
by a growing family of inhibitory receptors. These include
immunoglobulin G (IgG) receptor FcRIIB, killer inhibitory
receptors, and signal regulatory proteins, but PECAM-1 is the only
ITIM-bearing receptor reported to be expressed in platelets.14,15
Therefore, it has been proposed that PECAM-1 be assigned to the
immunoglobulin–ITIM family of receptors.14
The ligand-binding properties of PECAM-1 are complex. It has
the capacity for homophilic interactions3,16 and heterophilic interac-
tions with a number of molecules that include integrin v3 and
CD38.17,18 PECAM-1 becomes phosphorylated on tyrosine resi-
dues in response to a variety of stimuli that include PECAM-1
cross-linking,19 activation of the high-affinity receptor for IgE
(FcRI),20 shear stress,21 and oxidative stress.22 Furthermore, we
have recently reported that platelet activation through the collagen
receptor glycoprotein VI (GPVI) and through thrombin receptors
results in PECAM-1 tyrosine phosphorylation and that this is not
dependent on platelet aggregation and secretion,23 though tyrosine
phosphorylation is enhanced by aggregation.24 The tyrosine resi-
dues that become phosphorylated in PECAM-1 have been mapped
and fall within the ITIM.25 Phosphorylated ITIMs recruit signaling
molecules, such as the tyrosine phosphatases SHP-1 and SHP-2,
which bind to the motif through Src-homology 2 domain interac-
tions. Indeed, both SHP-1 and SHP-2 have been shown to associate
with tyrosine-phosphorylated PECAM-1,24-26 and PECAM-1 ITIM
phosphopeptides activate these phosphatases in vitro.19,25,26 Gener-
ally, these protein tyrosine phosphatases exhibit inhibitory effects
by counteracting tyrosine kinase–dependent pathways, though
SHP-2 has been shown to positively regulate growth factor
receptor signaling.27
Immunoreceptor tyrosine-based activatory motif (ITAM)–
bearing receptors have a critical place in the regulation of platelet
function.28 Indeed, the collagen receptor GPVI-FcR -chain
complex signals through an ITAM on the cytoplasmic tail of the
FcR -chain.29-33 Several studies in other cell systems have
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provided evidence of an antagonistic relationship between ITAM-
and ITIM-containing receptors when they are expressed on the
same cell. An example of this is the receptor for IgG FcRIIB
(ITIM), which negatively regulates cell activation stimulated by
FcRIIA (ITAM).34
In this study we examined the effect of PECAM-1 signaling on
the activation of human platelets. We demonstrate that the activa-
tion of PECAM-1 signaling by antibody-mediated cross-linking
results in the inhibition of collagen-mediated activation; similar
results were obtained using a GPVI-selective agonist convulxin
(Cvx). Furthermore, we present evidence to indicate that the
inhibitory functions of PECAM-1 may not be restricted to the
inhibition of ITAM-containing receptor signaling pathways be-
cause thrombin-stimulated activation was also inhibited. Inhibition
of platelet activation is accompanied by a concomitant inhibition of
platelet protein tyrosine phosphorylation and decreased levels of
calcium mobilization from intracellular stores. Our data support the
notion that PECAM-1 signaling may be involved in the regulation
of platelet function in vivo.
Materials and methods
Materials
Horm-Chemie collagen (collagen fibers from equine tendons) was pur-
chased from Nycomed (Munich, Germany). Cvx was purified from the
venom of the rattlesnake (Crotalus durissus terrificus), as described
previously.35 Thromboxane mimetic U46619 and adenosine diphosphate
(ADP) was purchased from Sigma (Poole, United Kingdom). Antiphospho-
tyrosine monoclonal antibody (mAb) (4G10) was obtained from Upstate
Biotechnology (TCS Biologicals, Buckinghamshire, United Kingdom).
Anti–PECAM-1 antibodies were obtained as follows: monoclonal antibody
HC1/6, from Serotec (Oxford, United Kingdom); polyclonal anti–
PECAM-1 (C-20) and monoclonal antibody AB468, from Autogen Bio-
clear (Wiltshire, United Kingdom); and monoclonal antibody PECAM-1.3,
kindly provided by Professor Peter Newman (The Blood Center of
Southeastern Wisconsin, Milwaukee). Control mouse IgG1 was purchased
from Sigma (Poole, United Kingdom). Monoclonal antibody IV.3 was
purified from hybridoma cell culture medium, and F(ab)2 fragments were
generated by pepsin digestion using reagents purchased from Pierce (Perbio
Scientific, Chester, United Kingdom). Horseradish peroxidase–conjugated
secondary antibodies and the enhanced chemiluminescence detection
system were purchased from Amersham Pharmacia Biotech (Buckingham-
shire, United Kingdom). Fura-2 AM was from Molecular Probes (Cam-
bridge Bioscience, United Kingdom). All other reagents were from
previously described sources.23,32
Preparation and stimulation of platelets
Human platelets from drug-free donors were prepared on the day of the
experiment by differential centrifugation, as described previously,32 and
suspended in modified Tyrode-HEPES buffer (134 mM NaCl, 0.34 mM
Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose,
1 mM MgCl2, pH 7.3) to a density of 2  108 cells/mL. For protein
precipitation experiments, platelets were resuspended at 8  108 cells/mL
in buffer containing 1 mM EGTA to prevent aggregation. Stimulation of
platelets (450 L) with collagen, Cvx, and thrombin (delivered in 50 L)
was performed at 37°C in an optical platelet aggregometer (Chrono-log,
Havertown, PA) with continuous stirring (1200 rpm). PECAM-1 activation
was stimulated by incubation with anti–PECAM-1 antibodies (AB468, 1
g/mL) or PECAM 1.3, 10 M (g/mL)) for 5 minutes, followed by
incubation for 90 seconds with F(ab)2 fragments of anti-IgG secondary
antibodies (30 g/mL) to cross-link. Monoclonal antibody AB468 was
generated against full-length PECAM-1 ectodomain, and the precise
binding epitope has not been mapped. The binding epitope of PECAM 1.3
has been mapped to immunoglobulin domain 1.12 Control experiments were
performed using an irrelevant isotype-matched antibody in place of AB468
or PECAM 1.3 and were used at the same concentration. In some
experiments, the low-affinity receptor for IgG was blocked by incubation
with a saturating concentration (1 g/mL) of F(ab)2 fragments of mAb IV.3
for 5 minutes. Saturating concentrations of mAb IV.3 antibody were
established by determining the concentration of F(ab)2 fragment that
completely inhibited subsequent whole IgG–mediated FcRIIA cross-
linking and platelet activation (as described previously36). Platelet aggrega-
tion was determined by optical aggregometry.
Immunoprecipitation studies
Platelet stimulation was terminated by the addition of an equal volume of
ice-cold lysis buffer (2% (vol/vol) Nonidet P40, 20 mM Tris, 300 mM
NaCl, 10 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 2 mM Na3VO4,
10 g/mL leupeptin, 10 g/mL aprotinin, 1 g/mL pepstatin A, pH 7.3).
Detergent-insoluble debris was removed, and the lysates were precleared by
mixing with protein A–Sepharose for 1 hour at 4°C (20 L of a 50%
(wt/vol) suspension of protein A–Sepharose in Tris-buffered saline–Tween
(TBS-T; 20 mM Tris, 137 mM NaCl, 0.1% (vol/vol) Tween 20, pH 7.6)).
Protein A–Sepharose was removed from the lysates before the addition of
anti–PECAM-1 antibody (HC1/6, 1 g). After rotation at 4°C for 1 hour,
0.5 L secondary antiserum was added (rabbit anti–mouse IgG) and mixed
for a further 30 minutes. Protein A–Sepharose suspension (25 L) was
added to each sample, and mixing continued for 1 hour before the
Sepharose pellet was washed in lysis buffer; this was followed by a wash
with TBS-T and by the addition of Laemmli sample-treatment buffer.
Proteins were separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions using 10% gels and
were transferred to polyvinylidene difluoride membranes by semidry
Western blotting.
Immunoblotting
Membranes were blocked by incubation in 10% (wt/vol) bovine serum
albumin dissolved in TBS-T. Primary and secondary antibodies were
diluted in TBS-T containing 2% (wt/vol) bovine serum albumin and were
incubated with membranes for 1 hour at room temperature. Blots were
washed for 2 hours in TBS-T after incubation with antibodies for 1 hour at
room temperature and were developed using an enhanced chemilumines-
cence detection system. Primary antibodies were used at a concentration of
1g/mL (antiphosphotyrosine, 4G10; anti-PECAM-1, C-20), and horserad-
ish peroxidase–conjugated secondary antibodies were diluted at 1:10 000.
5-Hydroxytryptamine secretion assay
Platelets were loaded with [3H]5-hydroxytryptamine (5-HT) by incubation
with 0.5 Ci/mL (18.5 kBq) platelet-rich plasma for 1 hour at 37°C.
Platelets were prepared from the platelet-rich plasma as described above.
Stimulation of platelets was terminated by the addition of an equal volume
of 6% glutaraldehyde and microcentrifugation, and the level of [3H]5-HT
release into the supernatant was determined by scintillation spectrometry.
[3H]5-HT release was expressed as a percentage of the total tissue content
after subtraction of release under basal conditions.
Measurement of [Ca]i by spectrofluorometry
Washed human platelets (prepared as above) were incubated at 2  109
cells/mL in calcium-free Tyrode HEPES buffer with 3 M Fura-2 AM for 45
minutes. Platelets were washed once and resuspended at 2  108 cells/mL
in modified Tyrode HEPES buffer. Stimulation of platelets (450 L) in the
presence of 2 mM EGTA with Cvx and thrombin (delivered in 50 L) was
performed with constant stirring at 37°C in a luminescence spectrophotom-
eter (LS-50B; Perkin-Elmer) with excitation wavelengths of 340 nm and
380 nm. Fluorescence emission was measured at a wavelength of 510 nm.
Where required, PECAM-1 was cross-linked before stimulation with
agonist as described above. The ratio of emission values (excitation
at 340/380 nm) was calculated and converted to calcium concentration
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using FLWinLab software (Perkin-Elmer) using the equation
[Ca]i 	 Kd  (R 
 Rmin)/(Rmax 
 R)  SFB, where R is emission ratio
value (340/380 nm). Rmax, the maximum 340/380 ratio, was determined by
lysing platelets with 25 M digitonin in the presence of 1 mM CaCl2. The
Rmin 340:380 nm ratio was obtained by adding 2 mM EGTA. Kd was the
dissociation constant of the Fura-2/Ca complex (224 nM), and SFB was
the fluorescence ratio at 340/380nm Rmin and Rmax).
Statistical analysis
Determination of statistical significance was performed using the Student
paired t test. Results are expressed as mean SEM.
Results
Cross-linking PECAM-1 inhibits collagen-stimulated
platelet aggregation
An antagonistic relationship has been reported between ITIM- and
ITAM-containing receptors when they are expressed in the same
cell.12,13,34 Because the platelet collagen receptor GPVI signals
through an ITAM on the FcR-chain with which it is associated, we
investigated the effect of PECAM-1 signaling on platelet activation
with collagen. PECAM-1 was activated by incubation with antibod-
ies specific for the ectodomain of PECAM-1 (AB468 (Figure 1) or
PECAM1.3, not shown) and was cross-linked with a secondary
antibody, (Fab)2 fragment. Consistent with findings from other
reports,19 this resulted in increased tyrosine phosphorylation of the
protein and did not result in the stimulation of platelet aggregation
(Figure 1A). Tyrosine phosphorylation of PECAM-1 was main-
tained on cross-linking in the presence of EGTA (1 mM), RGDS
peptide (0.5 mM), and -chain peptide of fibrinogen (100 M),
added separately or together (not shown). This, together with fact
that these experiments were performed on washed platelets,
indicates that the tyrosine phosphorylation of PECAM-1 on
cross-linking is not dependent on integrin IIb3 engagement. The
effect of PECAM-1 cross-linking for 90 seconds before stimulation
with collagen was found to have a marked inhibitory effect on
collagen-stimulated platelet aggregation. At lower concentrations
of collagen (eg, 10 g/mL), cross-linking of PECAM-1 before
agonist addition completely abolished aggregation (data not shown).
Figure 1Bii shows the marked inhibitory effect of PECAM-1
cross-linking on a high concentration of collagen (100 g/mL).
The use of an isotype-matched IgG control and cross-linker F(ab)2
had no effect on PECAM-1 tyrosine phosphorylation (not shown)
and collagen-stimulated platelet aggregation (Figure 1Bi). Results
are representative of 3 separate experiments. Similar results were
obtained using the alternative anti-PECAM-1 antibody, PECAM
1.3. In some experiments, the low-affinity receptor for IgG
FcRIIA was blocked before PECAM-1 cross-linking and agonist
stimulation using a saturating concentration of F(ab)2 fragments of
mAb IV.3. The inhibitory effect of PECAM-1 cross-linking was
unaltered under these conditions, indicating that the inhibitory
effect of PECAM-1 using antibodies was not caused by the
activation of FcRIIA. This result was not surprising given that the
activation of FcRIIA by cross-linking with antibodies results in
platelet activation.36
PECAM-1 cross-linking inhibits GPVI- and thrombin
receptor-mediated platelet aggregation
Given the marked effect of PECAM-1 signaling on collagen-
mediated platelet aggregation, we investigated whether this was
restricted to GPVI-mediated signaling. GPVI was stimulated using
the selective agonist Cvx, a protein purified from the venom of the
rattlesnake, C durissus terrificus. Aggregation stimulated with 15
ng/mL Cvx was completely inhibited by prior activation of
PECAM-1 (Figure 2Ai), and a partial inhibitory effect was
observed at higher concentrations of Cvx (31.25 and 62.5 ng/mL;
not shown and Figure 2Aii, respectively). Similar results were
observed on the stimulation of platelets with the G protein–coupled
receptor agonist thrombin. Complete inhibition of aggregation at
90-second stimulation was observed at a thrombin concentration of
0.05 U/mL (Figure 2Bi) and a partial effect at 0.1 U/mL (Figure
2Bii). The use of an isotype-matched IgG control and cross-linker
F(ab)2 had no effect on Cvx- or thrombin-stimulated platelet
Figure 1. Cross-linking of PECAM-1 inhibits collagen-stimulated platelet aggre-
gation. (A) PECAM-1 cross-linking on platelet surfaces results in its tyrosine
phosphorylation and does not stimulate platelet aggregation. (i) PECAM-1 was
immunoprecipitated from washed human platelets under resting conditions or after
PECAM-1 cross-linking. Proteins were separated by SDS-PAGE and immunoblotted
to detect phosphotyrosine residues (upper panel). Immunoprecipitation was verified
by reprobing for PECAM-1 (lower panel). (ii) PECAM-1 was cross-linked on washed
platelets (as described in “Materials and methods”), and aggregation was monitored
using optical aggregometry. (B) (i) Platelets were incubated with isotype-matched
control IgG for 5 minutes before the addition of F(ab)2 cross-linker for 90 seconds
and then were stimulated with collagen (100 g/mL). Aggregation was monitored
using optical aggregometry. (ii) Cross-linking of PECAM-1 inhibits collagen-
stimulated platelet aggregation. Platelets were stimulated with collagen (100 g/mL)
for 90 seconds with and without first cross-linking PECAM-1 and platelet aggregation
monitored by optical aggregometry. Data are representative of 3 separate experi-
ments. Tyr(P), tyrosine phosphorylation; PECAM-1 XL, PECAM-1 cross-linking.
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aggregation (Figure 2Ai-Bi). No inhibitory effect of PECAM-1
activation was observed at higher concentrations of thrombin (eg,
0.5 and 1, U/mL; data not shown). Results are representative of 5
separate experiments. Similar results were obtained using the
alternative anti–PECAM-1 antibody PECAM 1.3 and when
FcRIIA was blocked before PECAM-1 cross-linking.
Platelet secretion is inhibited by PECAM-1 signaling
Platelet activation is accompanied by secretion from dense gran-
ules. Dense granule secretion was assessed by measuring the
release of [3H]5-HT from preloaded washed platelets. Figure 3
shows the results of experiments to determine the effect of
PECAM-1 cross-linking on [3H]5-HT secretion. A significant
reduction in secretion was observed in platelets in which PECAM-1
was activated before stimulation with Cvx (81.9%  2.9% to
39.8%  4.1%; P 	 .02; n 	 3) or thrombin (70.9%  4.6% to
37.0%  8.0%; P 	 .01; n 	 3). The use of an isotype-matched
IgG control and cross-linker F(ab)2 had no effect on Cvx- or
thrombin-stimulated dense granule secretion (not shown). Experi-
ments performed in the presence of mAb IV.3 to block the Fc
receptor FcRIIA produced similar results.
PECAM-1 inhibits platelet protein tyrosine phosphorylation
The effect of PECAM-1 cross-linking on GPVI- and thrombin
receptor–stimulated signaling was investigated. Platelets were
stimulated with Cvx (15 ng/mL) or thrombin (0.05 U/mL) with or
without prior cross-linking of PECAM-1 for 90 seconds. Whole-
cell protein tyrosine phosphorylation levels were determined by
immunoblotting. Cross-linking PECAM-1 alone had no effect on
basal platelet tyrosine phosphorylation levels (Figure 4). Stimula-
tion with Cvx (15 ng/mL) or thrombin (0.05 U/mL) caused an
increase in the level of tyrosine phosphorylation of a broad range of
proteins, consistent with previous reports.32,37 In samples in which
PECAM-1 signaling was stimulated by cross-linking before incuba-
tion with Cvx or thrombin, total tyrosine phosphorylation was
reduced (Figure 4). The use of an isotype-matched IgG control and
cross-linker F(ab)2 had no detectable effect on Cvx- or thrombin-
stimulated total tyrosine phosphorylation levels.
PECAM-1 inhibits the mobilization of calcium from
intracellular stores
Stimulation of the collagen receptor GPVI and thrombin receptors
leads to rapid intracellular mobilization of calcium, an effect that is
essential for secretion and aggregation.38 Intracellular calcium
Figure 2. PECAM-1 cross-linking inhibits GPVI- and
thrombin receptor–stimulated platelet aggregation. (A)
Platelets were stimulated with Cvx at (i) 15 ng/mL and (ii)
62.5 ng/mL with and without first cross-linking PECAM-1,
and aggregation responses were monitored by optical
aggregation (arrow indicates the addition of Cvx). (B)
Platelets were stimulated with thrombin at (i) 0.05 U/mL and
(ii) 0.1U/mL with and without prior cross-linking of PECAM-1
(as described in “Materials and methods”). Platelet aggrega-
tion was monitored by optical aggregometry (arrow indi-
cates the addition of thrombin). Treatment of platelets with
isotype-matched control IgG before stimulation with Cvx (15
ng/mL) and thrombin (0.05 U/mL) is shown in A(i) and B(i),
respectively. Data are representative of 3 separate experi-
ments. PECAM-1 XL, PECAM-1 cross-linking.
Figure 3. Platelet-dense granule secretion is inhibited by PECAM-1 signaling.
Platelets were loaded with [3H]5-HT before stimulation with Cvx (62.5 ng/mL) or
thrombin (0.1 U/mL). Where required, PECAM-1 was cross-linked an agonist was
added (as described in “Materials and methods”). Secretion of [3H]5-HT into cell
medium was measured using scintillation spectrometry. [3H]5-HT release is ex-
pressed as a percentage of total tissue content after subtraction of basal secretion
values. Results represent mean  SE (n 	 3). Student t test was used to compare
PECAM-1 cross-linked and non–cross-linked sample for statistical significance.
*P  .05. PECAM-1 XL, PECAM-1 cross-linking
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levels were measured fluorometrically using the calcium-sensitive
dye Fura-2 AM. Experiments were performed in the presence of 2
mM EGTA to prevent the entry of extracellular calcium. Stimula-
tion of platelets with Cvx and thrombin resulted in a rapid increase
in the levels of intracellular calcium that declined over a period of
approximately 5 minutes (Figure 5). Incubation of platelets with
control antibody and cross-linker F(ab)2 caused no change in Cvx-
and thrombin-stimulated intracellular calcium mobilization (Figure
5A). Cross-linking of PECAM-1 for 90 seconds before incubation
with Cvx (62.5 ng/mL) or thrombin (0.1 U/mL) resulted in a
markedly reduced level of calcium mobilization (Figure 5Bi-Ci).
At the lower concentrations of agonists used (Cvx, 15 ng/mL;
thrombin, 0.05 U/mL), calcium mobilization was almost abolished
(Figure 5Bii-Cii). The effect of PECAM-1 cross-linking on the
reduction of peak intracellular calcium levels for a range of agonist
concentrations is shown in Figure 5Biii-Ciii. A reduction of at least
50% in calcium mobilization was observed at all concentrations of
Cvx and thrombin tested. Similar results were obtained using the
alternative anti–PECAM-1 antibody, PECAM 1.3. Furthermore,
experiments performed in the absence of extracellular EGTA
indicate that PECAM-1 cross-linking does not inhibit agonist-
induced influx of calcium (data not shown).
Discussion
Rapid and complete activation of platelets at sites of tissue damage
is ensured through numerous positive feedback pathways, mainly
through the actions of mediators such as thromboxane A2 and ADP
that are released from activated platelets. The existence of such a
rapid and reactive system emphasizes the need for effective
regulation of platelet function to prevent disorders such as thrombo-
sis and hemorrhage. Platelet reactivity is a controlled balance
between positive and negative regulatory factors and signaling
mechanisms. Much attention has recently been focused on the
identification of the receptors and signaling pathways that lead to
platelet activation, particularly on exposure to collagen,30,31,33
thrombin,39 and ADP.40 Negative regulatory mechanisms in plate-
lets are less well understood. The effects of endothelium-derived
prostacyclin and nitric oxide are recognized for their roles in
inhibiting platelet activation in healthy blood vessels. These molecules
inhibit activation through cyclic adenosine monophosphate– and
cyclic guanosine monophosphate–dependent signaling mecha-
nisms, respectively. We report here on a third negative regulation
system that is mediated through a cell-surface ITIM-bearing
adhesion receptor, PECAM-1.
Platelet collagen receptor GPVI signals through an ITAM
present on the cytoplasmic tail of the FcR-chain with which it is
associated. The basis for the hypothesis that PECAM-1 may be a
negative regulator of platelet activation was the presence of an
ITIM because in some contexts ITAM- and ITIM-containing
receptors have been reported to function in an antagonistic
fashion.34 Indeed, the activation of PECAM-1 by cross-linking has
been reported to inhibit signaling by T-cell and B-cell antigen
receptors, each of which signals through an ITAM.12,13 We have
reported previously that activation of GPVI or thrombin receptors
on platelets leads to tyrosine phosphorylation of PECAM-1 in an
integrin-independent manner,23 and other reports suggest that
thrombin receptor activatory peptide-mediated PECAM-1 tyrosine
phosphorylation is enhanced by integrin engagement.24 In addition,
platelet activation with Cvx or thrombin results in increased cell
surface exposure of PECAM-1.23 If PECAM-1 signaling is inhibitory in
platelets, this may form part of a negative feedback pathway.
PECAM-1 was stimulated through cross-linking using antibod-
ies directed to the extracellular domain of the receptor. This
strategy was chosen as the most specific manner through which to
activate PECAM-1, and activation was confirmed because cross-
linking stimulated its tyrosine phosphorylation. Confusion sur-
rounds the natural endogenous ligand for PECAM-1 on platelets in
vivo. As described earlier, PECAM-1 has been shown to participate
in homophilic and heterophilic ligand binding. One would antici-
pate that results similar to those described here would be obtained
using the recombinant extracellular domain of PECAM-1 as
ligand; however, results of such experiments may be complicated
by the ability of PECAM-1 to bind to other cell surface proteins. As
has been reported previously, PECAM-1 cross-linking stimulates
tyrosine phosphorylation (Figure 1) and association of SHP-2 (not
shown) but did not in itself cause platelet activation. Furthermore,
tyrosine phosphorylation of PECAM-1 on cross-linking appeared
not to be dependent on integrin IIb3 engagement, though we
cannot rule out the possibility that in vivo it may enhance this
effect. Cross-linking PECAM-1 for 90 seconds before stimulation
with collagen caused the inhibition of platelet aggregation. At
Figure 4. PECAM-1 signaling inhibits platelet protein tyrosine phosphorylation.
Platelet lysates were prepared in Laemmli buffer from nonstimulated platelets (stirred
with buffer alone) and platelets stimulated for 90 seconds with Cvx (15 ng/mL) or
thrombin (0.05 U/mL). Before stimulation, PECAM-1 was cross-linked in some
samples (A) or platelets were incubated with isotype-matched control IgG and
cross-linker F(ab)2 (B). Proteins were separated by SDS-PAGE under reducing
conditions and immunoblotted to detect protein tyrosine phosphorylation. PECAM-1
XL, PECAM-1 cross-linking
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lower concentrations of collagen, aggregation was inhibited com-
pletely, but even at high concentrations of collagen (100 g/mL)
PECAM-1 activation caused a substantial inhibition of aggrega-
tion. Because collagen is also able to bind other receptors on the
platelet, including the integrin 21, we examined the effect of
PECAM-1 cross-linking on GPVI-mediated platelet aggregation
using the specific agonist Cvx. Similar results were obtained, with
complete inhibition of aggregation at lower concentrations of
agonist (15 ng/mL) and partial effects at higher concentrations
(62.5 ng/mL). This suggests that PECAM-1 is a potent inhibitor of
GPVI-mediated (ITAM) platelet activation. This is consistent with
the findings of Patil et al,41 who have recently reported that
PECAM-1–deficient mouse platelets are hyperresponsive to colla-
gen and display enhanced collagen adhesion.
Experiments were conducted to determine whether the inhibi-
tory effect of PECAM-1 is restricted to signaling through ITAM-
containing receptors. On the contrary, PECAM-1 cross-linking was
also found to inhibit thrombin-stimulated platelet aggregation. It is
not possible to compare directly the potency of 2 different agonists
that mediate their effects through different receptors and signaling
pathways. However, no inhibitory effect of PECAM-1 was ob-
served at moderate concentrations of thrombin (0.5 and 1 U/mL;
results not shown), where dramatic levels of inhibition were
observed at high concentrations of collagen (100g/mL). PECAM-
1–mediated inhibition of thrombin-stimulated aggregation was
observed only at lower thrombin concentrations (complete inhibi-
tion with 0.05 U/mL and slight inhibition at 0.1 U/mL). This
suggests that PECAM-1 activation inhibits thrombin-stimulated
platelet aggregation less efficiently than it does collagen-stimulated
aggregation, consistent with the general inhibitory effect on platelet
aggregation by an antibody bound to PECAM-1 reported by Wu et
al.42 We also examined the effect of PECAM-1 cross-linking on
platelet aggregation stimulated by other G protein–coupled recep-
tor agonists. Aggregation in response to low concentrations of the
thromboxane mimetic U46619 was also reduced by PECAM-1
signaling (M.C. and J.M.G., unpublished results, May 2001). In
addition, preliminary work suggests that ADP-induced platelet
aggregation at low agonist concentrations may also be affected.
This is consistent with PECAM-1 performing a negative regulatory
role in the control of platelet activation stimulated by ITAM- and
non–ITAM-containing receptor agonists. Platelet responses that are
not dependent ITAM-bearing– or G protein–coupled receptors—
for example, ristocetin-induced agglutination—are not altered by
PECAM-1 signaling (results not shown). In contrast to our results,
thrombin- and ADP-stimulated platelet aggregation has been
reported to be normal in PECAM-1–deficient mouse platelets.11,41
In these 2 reports, the effect of removing the negative regulator
from platelets was investigated, whereas we examined the conse-
quences of stimulating the receptor to a high level. Our approach
was more likely to reveal more modest inhibitory effects, such as
those observed for thrombin, through which no change was
observed in removing PECAM-1 from the cells. Patil et al41 have
reported recently that PECAM-1–deficient platelets are hyperrespon-
sive to collagen and collagen-related peptide (CRP), but not to
thrombin.41 In assays of platelet aggregation and secretion, hyperre-
sponsiveness was almost completely lost at high concentrations of
collagen and CRP (10 g/mL and 5 g/mL, respectively). The
concentrations of thrombin used in their experiments were 0.1
Figure 5. PECAM-1 cross-linking inhibits the mobili-
zation of calcium from intracellular stores. Fura-2
AM–loaded human platelets were stimulated with either
Cvx or thrombin, and the mobilization of calcium was
measured fluorometrically as described in “Materials and
methods” (arrow indicates the addition of agonist). (A)
Treatment of platelets with control IgG and cross-linker
F(ab)2 has no effect on Cvx- and thrombin-stimulated
calcium mobilization. (B) (i, ii) Representative calcium
responses for stimulation with Cvx at 62.5 ng/mL and 15
ng/mL, respectively, with and without first cross-linking
PECAM-1. Traces are representative of 3 separate
experiments. (iii) PECAM-1–induced percentage reduc-
tion in peak levels of intracellular calcium stimulated by
62.5, 31.25, and 15 ng/mL Cvx. Data represent mean 
SE (n 	 3). C (i, ii) Representative calcium responses for
stimulation with thrombin at 0.1 U/mL and 0.05 U/mL,
respectively, with and without first cross-linking PE-
CAM-1. Traces are representative of 3 separate experi-
ments. (iii) PECAM-1–induced percentage reduction in
peak levels of intracellular calcium stimulated by 0.5, 0.1,
and 0.05 U/mL thrombin. Data represent mean  SE
(n 	 3). PECAM-1 XL, PECAM-1 cross-linking.
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U/mL and 1 U/mL. At these concentrations the results obtained
appeared similar to those seen at high concentrations of collagen or
CRP, particularly on aggregation traces. This suggests that hyperre-
sponsiveness to thrombin might have been masked because of the
relatively high concentrations used. Indeed, in our experiments in
which PECAM-1 was activated by cross-linking, the inhibition of
thrombin-stimulated responses were modest where 0.1 U/mL of
thrombin was used, and no inhibition was observed at higher
concentrations. We suggest that closer examination of responses in
PECAM-1–deficient platelets to lower concentrations of thrombin,
ADP, and U46619 may clarify this matter. The observation that
ITAM-mediated signaling is inhibited to a higher degree than
non-ITAM–mediated signaling is further supported by experiments
in platelets in which PECAM-1 was coligated with FcRIIA (an
ITAM-containing IgG receptor). Coligation resulted in the inhibi-
tion of FcRIIA-mediated platelet aggregation and intracellular
calcium mobilization stimulated by receptor cross-linking (M.C.
and J.M.G., unpublished data, December 2000). Platelet secretion
in response to Cvx and thrombin was also inhibited to a significant
level by PECAM-1 cross-linking. It is unclear whether the
inhibition of platelet aggregation after PECAM-1 cross-linking was
a consequence of reduced integrin IIb3 regulation or reduced
secretion of fibrinogen from -granules (these experiments were
performed on washed platelets; therefore, for aggregation, fibrino-
gen must be secreted). The inhibitory effects of PECAM-1 on
stimulation with agonists—such as the collagen Cvx, thrombin,
and the thromboxane mimetic U46619—suggest that PECAM-1
may inhibit primary signaling events and secondary stimulation by
factors released by activated platelets. Indeed, Nieswandt et al43
have recently reported cross-talk between GPVI and Gi-coupled
receptors for ADP and adrenaline. It is possible that the inhibition
of receptors that cross-talk with GPVI-mediated signaling may
contribute to the inhibitory actions of PECAM-1 on collagen- and
Cvx-stimulated activation. This may also explain why the inhibi-
tory functions of PECAM-1 on GPVI-mediated activation are more
effective than on thrombin-mediated activation.
Having established that PECAM-1 cross-linking inhibits plate-
let function, we examined the effect of this on some aspects of
signal transduction. Platelet activation by the collagen receptor
GPVI is dependent on tyrosine kinases and consequently is
associated with the rapid tyrosine phosphorylation of a wide
variety of platelet proteins. Stimulation with thrombin results in
protein tyrosine phosphorylation, but to a lesser degree. In this
study we have demonstrated that cross-linking PECAM-1, which
in itself does not alter whole-cell protein tyrosine phosphorylation
levels, inhibits substantially the level of tyrosine phosphorylation
induced by subsequent stimulation with Cvx or thrombin. This is
consistent with the reduction observed in aggregation and secre-
tion. The identities of the phosphoproteins whose phosphorylation
is reduced on PECAM-1 cross-linking is under investigation. It has
been reported that PECAM-1 stimulation by cross-linking inhibits
the mobilization of calcium from intracellular stores by the T-cell
antigen receptor.12 A recent report suggests that a similar effect is
seen with B-cell antigen receptors.13 Indeed, all the observations
presented in this report have been reproduced in platelets using one
of the anti–PECAM-1 antibodies used in the above 2 studies
(PECAM 1.3). Curiously, cross-linking PECAM-1 on endothelial
cells has been reported to stimulate increases in intracellular
calcium concentration.44 In the data presented here, we demon-
strate that underlying the PECAM-1–mediated inhibition of plate-
let activation is a significant level of inhibition of calcium release
from intracellular stores. As seen with aggregation assays, at lower
concentrations of Cvx and thrombin (15 ng/mL and 0.05 U/mL,
respectively), PECAM-1 signaling inhibits release almost com-
pletely, whereas a partial effect is observed at higher agonist
concentrations. Calcium mobilization is stimulated through the
intracellular generation of inositol 1,4,5-trisphosphate from phos-
phatidylinositol 4,5-bisphosphate by phospholipase C (PLC). It is
well established that in platelets, stimulation with collagen leads to
phosphorylation and activation of PLC2 isoform and that throm-
bin signaling regulates PLC.45,46,47 We have begun to investigate
the signaling that links PECAM-1 activation with the inhibition of
calcium mobilization generated by the collagen- and thrombin-
receptor signaling pathways by examining the production of
inositol phosphates. PECAM-1 cross-linking results in a substan-
tial and significant reduction in total inositol phosphates stimulated
by Cvx and thrombin (M.C. and J.M.G., unpublished data, May
2001). This suggests that PECAM-1 exerts its effects on collagen-
and thrombin-stimulated signaling either upstream of the PLC
isoforms or on these enzymes themselves. Much work must be
done, however, to establish how PECAM-1 signaling exerts its
effects on different platelet activation signaling pathways.
This report illustrates that PECAM-1, an ITIM-containing
receptor, is capable of regulating platelet function. However, its
role in vivo remains to be established. It is possible that this
molecule provides a mechanism to prevent platelet activation on
collision of platelets with healthy endothelium and collisions with
other platelets. PECAM-1 signaling may result in a negative
feedback on platelet activation pathways and thereby set the
threshold stimulation level for platelet activation. PECAM-1
ligation on platelet contact, and between platelets and healthy
endothelium, may also be instrumental in limiting the size of a
thrombus formation through inactivating platelets on the thrombus
periphery. A recent report by Vollmar et al45 using an in vivo
thrombosis model in PECAM-1 null mice suggests that PECAM-1
has no role in vascular thrombosis. This is surprising given the in
vitro data presented here and ex vivo studies on PECAM-1–
deficient platelets.41 This may be explained by the redundancy in
activation systems through which platelets may be stimulated given
that we show here that thrombin-induced platelet activation is less
sensitive to inhibition by PECAM-1. It is also highly likely that
additional ITIM-containing receptors are expressed on the platelet,
resulting in redundancy in inhibitory regulation systems. The above
report does not address the effect of PECAM-1 deficiency on larger
arterial vessels in which shear forces are likely to reach higher
levels and platelet thrombi may be encountered. This is a complex
area, further complicated by the potential roles of PECAM-1 in
endothelial cell function, and it requires greater investigation.
In conclusion, this report provides evidence for an extension of
the known roles of ITIM receptors in the negative regulation of
nonimmune cell function. In addition, in this study we have begun
to explain at the cell signaling level the inhibitory effects of
PECAM-1 on platelet activation. Future work is required to
determine precisely how PECAM-1 inhibits the signaling pathways
activated by multiple platelet agonists.
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